Combination of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: An open-label, single-arm, phase II clinical trial

被引：0
|
作者：
Jiang, Y-F. [1 ]
Bei, W-X. [1 ]
Wang, L. [2 ]
Xu, C. [2 ]
Lu, N. [3 ]
Liang, H. [4 ]
Ke, L-R. [3 ]
Ye, Y-F. [5 ]
Fang, T. [1 ]
He, S. [6 ]
Dong, S-H. [1 ]
Liu, Q. [1 ]
Zhang, C. [1 ]
Xia, W. [1 ]
Zhao, C. [1 ]
Xie, C. [7 ]
Liu, G. [8 ]
Xiang, Y-Q. [1 ]
机构：
[1] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ Canc Ctr, Dept Radiat Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ Canc Ctr, Dept Radiol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ Canc Ctr, Dept Nasopharyngeal Carcinoma, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[5] Sun Yat Sen Mem Hosp, Clin Res Design Div, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Radiat Oncol, Guang Zhou, Peoples R China
[7] NCI, Thorac & GI Malignancies Branch, Bethesda, MD USA
[8] Sun Yat Sen Univ, Radiotherapy Dept, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
893P
引用
收藏
页码：S633 / S634
页数：2
相关论文
共 50 条
  • [11] Anti-PD-1 antibody therapy for epithelial skin malignancies An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study)
    Ishii, Maki
    Hirai, Ikuko
    Tanese, Keiji
    Fusumae, Takayuki
    Nakamura, Yoshio
    Fukuda, Keitaro
    Uchi, Hiroshi
    Kabashima, Kenji
    Otsuka, Atsushi
    Yokota, Kenji
    Yamazaki, Naoya
    Namikawa, Kenjiro
    Fujimura, Taku
    Takenouchi, Tatsuya
    Yamamoto, Yuki
    Nishiguchi, Mana
    Sato, Yasunori
    Amagai, Masayuki
    Funakoshi, Takeru
    MEDICINE, 2020, 99 (44) : E22913
  • [12] An open-label, single arm, phase II trial of niraparib in combination with anti-PD1 antibody in recurrent/advanced stage endometrial cancer patients
    Li, J.
    Wei, W.
    ANNALS OF ONCOLOGY, 2021, 32 : S772 - S772
  • [13] Clinical trial data of Anti-PD-1/PD-L1 therapy for recurrent or metastatic nasopharyngeal Carcinoma: A review
    Adkins, Douglas R.
    Haddad, Robert I.
    CANCER TREATMENT REVIEWS, 2022, 109
  • [14] A Single-Arm Multi-Center Phase II Clinical Trial of Cadonilimab (anti-PD-1/CTLA-4) in Combination with or without Conventional Second-Line Treatment for Patients with Extensive Stage Small Cell Lung Cancer
    Chen, Can
    Chen, Minjun
    Bai, Yuju
    Li, Yajun
    Peng, Jie
    Yao, Biao
    Feng, Jiangping
    Zhou, Jian-Guo
    Ma, Hu
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2024, 23
  • [15] Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial
    Shukui Qin
    Jin Li
    Haijun Zhong
    Chuan Jin
    Lili Chen
    Xianglin Yuan
    Qingxia Fan
    Kehe Chen
    Peiguo Cao
    Jianjun Xiao
    Da Jiang
    Tao Zhang
    Hongyu Zhang
    Xicheng Wang
    Wei Wang
    Lin Han
    Qingyu Wang
    Jun Zhu
    British Journal of Cancer, 2022, 127 : 2249 - 2249
  • [16] Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.
    Wu, Xiaohua
    Xia, Lingfang
    Zhou, Qi
    Zhu, Jianqing
    Wang, Ke
    Chen, Jie
    Huang, Yi
    Kurb, Gulina
    Chang, Baoping
    Zhao, Weidong
    Wang, Xia
    Yang, Yingjie
    Lin, Zhongqiu
    Luo, Xiaoyong
    Lou, Ge
    Wang, Chunyan
    Wang, Jing
    Meng, Haijin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: A phase 1, open-label study in advanced malignancies
    Hamid, O.
    Chow, L. Q.
    Sanborn, R. E.
    Marshall, S.
    Black, C.
    Gribbin, M.
    McDevitt, J.
    Karakunnel, J. J.
    Gray, J. E.
    ANNALS OF ONCOLOGY, 2016, 27
  • [18] An open-label, single-arm, multi-institutional phase II trial of avelumab for recurrent, metastatic nasopharyngeal carcinoma.
    Sacco, Assuntina Gesualda
    Messer, Karen
    Leidner, Rom S.
    Colevas, A. Dimitrios
    Nieva, Jorge J.
    Chau, Nicole Grace
    Nangia, Chaitali Singh
    Pinsky, Benjamin
    Gold, Kathryn A.
    Daniels, Gregory A.
    Cohen, Ezra E. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [19] The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
    Xu, Da
    Wang, Hongwei
    Bao, Quan
    Jin, Kemin
    Liu, Ming
    Liu, Wei
    Yan, Xiaoluan
    Wang, Lijun
    Zhang, Yanqiao
    Wang, Guangyu
    Ma, Yue
    Ma, Zhigang
    Zhang, Chunhui
    Tang, Jiebing
    Wang, Sha
    Pang, Jiaohui
    Xu, Ting
    Wang, Kun
    Xing, Baocai
    NATURE COMMUNICATIONS, 2025, 16 (01)
  • [20] Combining radiation therapy with anti-PD-1 for patients with advanced hepatocellular carcinoma: An open-label, single-center, single-arm clinical study.
    Li, Jian-Xu
    Su, Ting-Shi
    Lin, Xiao-Feng
    Chen, Yi-Tian
    Liang, Shi-Xiong
    Xiang, Bang-De
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345